Zymeworks Inc. · NASDAQ:ZYME
Zymeworks — Investor Presentation (November 2017)
32 slides from Zymeworks's investor presentation, November 2017
Slide 1: Zymeworks Corporate Overview
ZYMEWORKS CORPORATE OVERVIEW
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes “forward-looking statements” within the meaning of U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statemen
Slide 3: A Clinical-Stage Biopharmaceutical Company Developing Multifunctional Therapeutics for Oncology
A Clinical-Stage Biopharmaceutical Company Developing Fit-for-Purpose, Multifunctional Therapeutics for Oncology Complementary Next-Generation Platforms Azymetric™ ZymeLink™ EFECT™ AlbuCORE™ Marquee Strategic Partnerships Wholly-Owned ZW25: Bispecific antibody in Phase 1 for HER2-expressing cancers
Slide 4: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 5: Next-Generation Therapeutic Platforms
Next-Generation Therapeutic Platforms ™ ™ ™ ™ PAGE 5
Slide 6: Complementary Therapeutic Platforms
Complementary Therapeutic Platforms Flexibility to engineer fit-for-purpose biotherapeutics to maximize therapeutic effect Azymetric Bispecifics™ ZymeLink™ AlbuCORE™ Bispecific Fab Hybrid Alternate Drug Antibody- Formats Formats Formats Conjugates Alternatives EFECT™ Immune Modulation PAGE 6
Slide 7: Zymeworks' Fully Integrated Drug Development Engine
Zymeworks’ Fully Integrated Drug Development Engine Inhibition of Potent Multiple ADC Pathways Payloads Biparatopic- Dual- Enhanced Targeting Payload of Receptors Complementary Delivery Target Discovery, Therapeutic Platforms Highly- Selection and Customized Antibody Azymetric™ ZymeLink™ Fit-for-Pur
Slide 8: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 9: Strategic Partnerships and Collaborations
Strategic Partnerships and Collaborations Remaining Enabling Potential Milestones Partners Events Programs Platform(s) ($ millions US) Announced:2011 Milestone #1: 2012 Multiple AzymetricTM 186 Milestone #2: 2013 Up to 3 EFECTTM Expanded: 2014 Announced: 2014 Expanded: 2014 Multiple Up to 4 Azymetri
Slide 10: Flexible Platforms Will Allow Further Pipeline Expansion
Zymeworks’ Flexible Platforms Will Allow Further Pipeline Expansion and Broader Therapeutic Area Applications Future Autoimmune Inflammation Today Broader Oncology Broader Oncology Underserved Underserved Underserved Oncology Oncology Oncology Multiple Active Future Discovery ZW25 & ZW33 Discovery P
Slide 11: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 12: Zymeworks' Wholly-Owned Product Candidates and Discovery Programs
Zymeworks’ Wholly-Owned Product Candidates and Discovery Programs PAGE 12
Slide 13: ZW25 – Bispecific for HER2-Expressing Cancers
ZW25 – Bispecific for HER2-Expressing Cancers Updated Safety & Anti-Tumor Activity Scheduled for SABCS 2017 • Biparatopic - targets two distinct HER2 epitopes Unique • Increased binding density Mechanisms • Potent effector-mediated cytotoxicity of Action • Blocks ligand-dependent and -independent tu
Slide 14: ZW25 – Biparatopic HER2 Binding Drives Unique Mechanisms of Action
ZW25 – Bispecific for HER2-Expressing Cancers Biparatopic HER2 Binding Drives Unique Mechanisms of Action • ZW25 targets two distinct HER2 epitopes (biparatopic) leading to unique binding geometries • Biparatopic Trans Binding – Each HER2 receptor can be targeted by two ZW25 antibodies • Monoclonal
Slide 15: ZW25 – Biparatopic HER2 Binding Drives Unique Mechanisms of Action
ZW25 – Bispecific for HER2-Expressing Cancers Biparatopic HER2 Binding Drives Unique Mechanisms of Action • ZW25’s unique binding geometries promote: • Extended chain formation and HER2 receptor clustering • Enhanced HER2 internalization and downregulation • Increased tumor cell binding density and
Slide 16: HER2 Classification for Breast Cancer
HER2 Classification for Breast Cancer HER2 HER2 HER2 HER2 HER2 Status High Intermediate Low Negative HER2 High 15.2% HER2 Intermediate IHC 2+, IHC 3+, IHC FISH IHC 1+, FISH 25.9% HER2 Assay IHC 0 or FISH Results 2+ or FISH Equivocal Equivocal or Negative HER2 Negative Positive or FISH FISH Negative
Slide 17: ZW25 – Adaptive Clinical Trial Design
ZW25 – Adaptive Clinical Trial Design Phase 1 2017 Data Flow 2016 2017 Phase 1 Trial Details Q3 Q4 Q1 Q2 Q3 Q4 First-in-human, open-label dose escalation and Phase 1 expansion cohort studies Dose Escalation • Patient Eligibility: Locally-advanced (unresectable) or metastatic 5;10;15 mg/kg weekly sol
Slide 18: ZW25 – Single Agent Anti-Tumor Activity
ZW25 – Single Agent Anti-Tumor Activity Target Lesions Decrease in Majority of Breast and GE Patients with Measurable Disease1 +60% % Change in Target Lesion SLD +40% 5 mg/kg 10 mg/kg 15 mg/kg +20% Prior % decrease * * * 0% * * PD due to new lesion -20% RECIST 1.1 response -40% -60% GE Breast Breast
Slide 19: ZW25 – Single Agent Anti-Tumor Activity
ZW25 – Single Agent Anti-Tumor Activity Time on Study: Breast and GE Cancer Patients Breast (1-001) 5 mg/kg (4-001) PD (target lesion) 10 mg/kg (4-003) PD (symptomatic brain met) 15 mg/kg (4-005) Physician decision (3-004) PD (leptomeningeal disease) Missed dose (1-002) PD (new bone met) PD, continu
Slide 20: ZW25 – Breast Cancer - Preliminary Phase 1 Dose Escalation Data
ZW25 – Breast Cancer - Preliminary Phase 1 Dose Escalation Data • Best response : 4 PR, 1 SD, 3 PD (DCR = 63%) • Median time on study 139 days (range: 54-329+) • Median 6 prior HER2-targeted regimens for metastatic disease • Patients with PD due to CNS metastases had systemic SD or PR at time of pro
Slide 21: ZW25 – Gastro Esophageal Cancer - Phase 1 Dose Escalation Data
ZW25 – Gastro Esophageal Cancer - Phase 1 Dose Escalation Data • Best response: 1 SD, 3 PD; DCR = 25% • Patient with SD on study > 6 months • Median 4 prior systemic regimens Prior # Prior # Prior Years Archival/Fresh Time on Dose Approved HER2 Systemic Best Patient Since HER2 Status Study Status/Co
Slide 22: ZW25 – Adaptive Clinical Trial Design
ZW25 – Adaptive Clinical Trial Design Phase 1 Cohort Expansion and Registrational Path 2016 2017 2018 2019 2020 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Phase 1 Dose Escalation 5;10;15 mg/kg weekly 20 mg/kg bi-weekly Top- ASCO ESMO SABCS Line 2017 2017 2017 Data Single Agent Cohort Expansion
Slide 23: ZW25 – FDA-Granted Orphan Designation for Gastric and Ovarian Cancer
ZW25 – FDA-Granted Orphan Designation for Gastric and Ovarian Cancer HER2-High Gastric Cancer PDX HER2-High Ovarian Cancer CDX PAGE 23
Slide 24: ZW33 – Bispecific ADC for HER2-Expressing Cancers
ZW33 – Bispecific ADC for HER2-Expressing Cancers Phase 1 Trial Initiation in H2 2017 • Biparatopic - targets two distinct HER2 epitopes Unique • Increased binding density Mechanisms • Enhanced HER2 internalization to of Action • deliver a potent cytotoxin • down-regulate HER2 signaling Superior ant
Slide 25: ZW33 – Bispecific ADC Efficacy in Breast Cancer PDX
ZW33 – Anti-HER2 Biparatopic Bispecific ADC Efficacy Trastuzumab-Resistant HER2-High Breast Cancer PDX • ZW33* demonstrates superior tumor growth inhibition as compared to other HER2-targeted therapies *prior to affinity optimization PAGE 25
Slide 26: ZW33 – Bispecific ADC Efficacy in Ovarian Cancer PDX
ZW33 – Anti-HER2 Biparatopic Bispecific ADC Efficacy HER2-Expressing Ovarian Cancer PDX • Treatment with ZW33 promotes complete responses ZW33 T-DM1 Efficacy Criteria (n=10) (n=10) Tumor Growth Inhibition (%) 313% 65% 3D RECIST Scores Complete Response 8 0 Partial Response 2 1 Stable Disease - 3 Pro
Slide 27: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 28: Milestones
Milestones 2017 Milestones ü ZW25: Top-line data from the dose escalation portion of Phase 1 clinical trial (Q1 2017) ü ZW25: Safety and preliminary anti-tumor activity data at ASCO (June 2017) ü ZW25: Additional dose escalation data at ESMO (Sept 2017) q ZW25: Dose escalation and cohort expansi
Slide 29: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 30: Zymeworks Management Team
Zymeworks Management Team Ali Tehrani, Ph.D. Founded Zymeworks in 2003. Current Board member of LifeSciences BC, Creatus Biosciences President & Chief Executive Officer Inc., CQDM and a member of the BC Premier’s Tech Council. Past member of the MITACS and BIOTECanada Advisory Boards and Committees.
Slide 31: Zymeworks Board of Directors
Zymeworks Board of Directors Nick Bedford Independent consultant. Former Chairman of the Board of ActiveState Corp. and Head of Chairman German Equities at UBS Kenneth J. Hillan, M.B., Ch.B. Achaogen’s Chief Executive Officer and a member of its Board of Directors since October 2011 Hollings Renton,
Slide 32: Zymeworks Corporate Overview
ZYMEWORKS CORPORATE OVERVIEW